ASX Health Stocks: HeraMed jumps 11pc on survey results, while Acrux seeks FDA approval for acne gel

The ASX 200 health stocks index (XHJ) fell slightly by 0.12% this morning, compared to the broader ASX 200 index which climbed by 0.16%.

Medical data and tech company HeraMed (ASX:HMD) jumped by 11%, after providing interim results from a paid pilot survey with Obstetrix Medical Group, an affiliate of NYSE-listed Mednax.

HeraMed says the results showed that feedback from both expecting mothers and clinicians toward the use of the HeraCARE plan have all been very positive.

Around 89% of patients said they were very positive toward the HeraCARE care plan, and 100% of the professional care team (physicians and midwives) indicated they believe the HeraCARE platform was safe and effective and would recommend it to others.

The HeraCARE is a digital platform enabling a new model of care for women throughout pregnancy, which includes a set of connected, digital tools for simple home use.

Mednax meanwhile, is a US$2.7bn company managing one of the largest providers of women’s and children’s physician services in the US.

HeraMed share price today:

Other ASX healthcare stocks with notable announcements

Acrux Limited (ASX:ACR) +1.5%

The skin-focused biotech company has submitted an Abbreviated New Drug Application (ANDA) to the US FDA for its generic version of Dapsone Gel, 5% used to treat acne.

The FDA has notified Acrux that the submission is sufficiently complete to be accepted for review.

The product helps decrease the number and severity of acne pimples, and helps pimples that do develop to heal more quickly.

According to Acrux, the total addressable market for the product including existing generics is US$30 million. There is currently just one other approved and marketed ANDA product in the market.

ImpediMed (ASX:IPD) unchanged

The medtech company said that two abstracts are being presented at the prestigious Heart Failure Society of America (HFSA) Annual Scientific Meeting held on September 10 – 13.

The abstracts demonstrate that bioimpedance spectroscopy offers an objective measure of heart failure stability during a viral pandemic, and has further shown the value of IPD’s SOZO digital platform.

“The data from these poster presentations adds to our growing body of clinical evidence for heart failure, said Richard Carreon, CEO of ImpediMed.

“We believe, in time, our technology can aid clinicians with both diagnosis and therapies associated with managing heart failure patients, resulting in improved outcomes.”

Telix (ASX:TLX) -0.32%

The cancer-focused biotech company has just signed a distribution agreement with Italian-based company, Radius.

Under the terms, Radius will be the exclusive commercial distributor of Illuccix, Telix’s prostate cancer investigational imaging product, in Italy.

Telix says that Radius is the market leader in the supply of gallium generators across Italy, a position which enables it to provide a secure supply of the Ga necessary for launching Illuccix.

Melbourne-based Telix is focusing on developing odiagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).

Neuren Pharma (ASX:NEU) -5.3%

The brain-focused health company is raising $20m in a private placement to accelerate its NNZ-2591 drug towards a Phase 3 clinical trial.

The funds will accelerate the development and increase the value of NNZ-2591 for four neuro-developmental disorders : Prader-Willi, Phelan-McDermid, Angelman and Pitt Hopkins syndromes.

Neuren says positive results would enable its US partner Acadia Pharmaceuticals to submit a New Drug Application (NDA) to the US FDA, and enable the company to engage commercial partners for Europe and Asia in 2022.

If a NDA is approved by the FDA and trofinetide is launched in the US for Rett Syndrome, Neuren would earn a revenue of approximately $111 million, plus double-digit percentage royalties on net sales.